Advertisement
UK markets close in 7 hours 12 minutes

  • FTSE 100

    8,084.80
    +39.99 (+0.50%)
     

  • FTSE 250

    19,811.96
    +12.24 (+0.06%)
     

  • AIM

    756.47
    +1.60 (+0.21%)
     

  • GBP/EUR

    1.1628
    -0.0000 (-0.00%)
     

  • GBP/USD

    1.2429
    -0.0023 (-0.19%)
     

  • Bitcoin GBP

    53,580.43
    +445.51 (+0.84%)
     

  • CMC Crypto 200

    1,436.30
    +12.20 (+0.86%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,331.80
    -10.30 (-0.44%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,176.31
    +347.38 (+2.06%)
     

  • DAX

    18,214.90
    +77.25 (+0.43%)
     

  • CAC 40

    8,117.39
    +11.61 (+0.14%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

CureVac strikes COVID-19 vaccine alliance deal with Bayer - Bild

Reuters
·1-min read
Outbreak of the coronavirus disease (COVID-19) in Tuebingen

FRANKFURT (Reuters) - German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.

Under the deal, Germany's Bayer will provide access to international pharmaceutical markets as well as its global supply chain and distribution network, the tabloid newspaper reported in an excerpt made available to Reuters ahead of publication. The report did not specify its sources.

The report did not disclose financial terms.

Bayer and CureVac were not immediately available for comment.

ADVERTISEMENT

CureVac last month started a large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.

(Reporting by Ludwig Burger; Editing by Sam Holmes)